Retatrutide Peptide Cas No.2381089-83-2

1. Weight loss effect

Significant appetite suppression: By activating GLP-1 and GIP receptors in the central nervous system, the body's desire and intake of food are reduced.

Promote energy expenditure: Activate glucagon receptors, enhance metabolism and energy expenditure of adipose tissue, and promote fat breakdown.

Delaying gastric emptying: Slowing down the rate of gastric contents emptying, prolonging satiety, and reducing the frequency of eating.

2. Blood glucose regulation function

Promote insulin secretion: Enhance the sensitivity of pancreatic beta cells to blood sugar, promote insulin secretion, and help control blood sugar.

Lowering blood glucose levels: By acting on multiple receptors, improving postprandial blood glucose fluctuations and reducing fasting and postprandial blood glucose.

Improving insulin resistance: Enhancing the body's sensitivity to insulin and promoting glucose metabolism balance.

3. Metabolic comprehensive benefits

Improving lipid metabolism: helps to reduce blood lipid abnormalities, improve blood lipid profile, and reduce the risk of cardiovascular disease.

Relieve metabolic syndrome: By comprehensively regulating body weight, blood glucose, and lipids, alleviate pathological states related to metabolic syndrome.

Potential cardiovascular protective effects: Some studies have shown that GLP-1 and GIP receptor agonists can improve cardiovascular function and help reduce the incidence of cardiovascular events.

4. Other potential functions

Improving liver fat accumulation: may help reduce liver fat deposition associated with non-alcoholic fatty liver disease (NAFLD).

Improving quality of life: By reducing weight and controlling blood sugar, the overall health status and quality of life of patients can be improved.

Multi receptor activation brings more comprehensive metabolic regulation effects.

May improve patients' medication adherence and treatment effectiveness.

It may become a new generation of drug choice for the treatment of obesity and diabetes in the future.

GLP-1 receptor activation: promotes insulin secretion, inhibits gastric emptying, and reduces appetite.

GIP receptor activation: enhances pancreatic beta cell function and increases insulin sensitivity.

Glucagon receptor activation: promotes energy expenditure and fat breakdown, helping with weight loss.

The synergistic effect of the triple mechanism effectively regulates metabolic balance, achieving a dual effect of weight loss and improving blood sugar.

1. Treatment of obesity:

By suppressing appetite and promoting energy expenditure, significant and lasting weight loss can be achieved, improving patients' metabolic status and quality of life.

2. Adjuvant treatment of type 2 diabetes:

Type 2 diabetes and obesity patients, used to improve blood sugar control

By increasing insulin secretion and improving insulin sensitivity, blood glucose levels can be controlled.

3. Metabolic syndrome management:

Mainly manifested in indications and comprehensive improvement of metabolic indicators

4. Potential applications:

Non alcoholic fatty liver disease, indirectly reducing the risk of cardiovascular disease

Obesity treatment: By significantly suppressing appetite and promoting energy metabolism, weight loss can be achieved.

Type 2 diabetes management: Improve blood sugar control, increase insulin secretion and sensitivity.

Metabolic syndrome: Expected to improve blood lipid abnormalities and cardiovascular risk factors.

● Clinical trials have shown that ritaglutide is significantly superior to existing single GLP-1 receptor agonists in weight loss.

● Good safety, common adverse reactions include gastrointestinal reactions (such as nausea, vomiting, diarrhea), which are mostly mild and temporary.